State-of-the-industry video lectures by leading urology experts
Latest Videos
Featured Videos

SAN FRANCISCO, CA USA ( - Dr. Vincent Launay-Vacher presented results from the MARS (Management of Antiangiogenics Renovascular Safety) study, a prospective multi-center study of renovascular tolerance of anti-VEGF drugs (AVD) in multiple different tumor types.

The authors’ goal was to assess the prevalence of renovascular abnormalities before treatment with anti-angiogenic drugs. The incidence of hypertension (HTN) and proteinuria (PU) were assessed both prior to initiation of anti-angiogenic therapy and following treatment. Patients included were naïve of any previous AVD, and had standard indications for treatment with AVD. Demographic, oncological, and renovascular data were collected and compared.

gucancerssympalt thumbIn total, 1 124 patients were studied; 137 had RCC, and 112 were treated with sunitinib. Median age was 61 years, and visceral, bone, and brain metastases were present in 71%, 42%, and 12.5% of patients, respectively. Sunitinib was administered at usual doses. Treatment duration was > 6 or > 12 months in 70.5% and 50.8%, respectively. At baseline, HTN and PU were present in 43.8% (grade 3 in 4.5%) and 15.6%, respectively. During follow-up after treatment with sunitinib, 75.0% developed PU (4.5% grade 3), and 21.4% developed HTN (14.3% grade 3). Overall, no thrombotic micro-angiopathy was reported, indicating it remains a rare side effect of anti-VEGF therapy.

The prevalence of renovascular abnormalities in patients with mRCC prior and following initiation of sunitinib is high. Thorough evaluation of renovascular status should be performed in all patients prior to initiation of AVD therapy. Follow-up of renovascular status should be performed in all patients.

Highlights of a presentation by Vincent Launay-Vacher, MD at the 2014 Genitourinary Cancers Symposium - January 30 - February 1, 2014 - San Francisco Marriott Marquis - San Francisco, California USA

Pitie-Salpetriere Hospital, Paris France

Written by Jeffrey J. Tomaszewski, MD, medical writer for

View Full 2014 GU Cancers Symposium Coverage



Publications focusing on urological cancer treatments through original commentary & articles
Everyday Urology Volume 3 Issue 2

Everyday Urology™ - Oncology Insights

From the Editor

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor


Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.


Upcoming educational events
October 19-23, 2018 / European Society for Medical Oncology 2018 Congress
European Society for Medical Oncology 2018 Congress
October 19-20, 2018 / Hilton New York JFK Airport Hotel
16th International Conference on Nephrology & Therapeutics
October 19-20, 2018 / Hilton New York JFK Airport Hotel
3rd Annual Kidney Congress